<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717843</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0790</org_study_id>
    <nct_id>NCT04717843</nct_id>
  </id_info>
  <brief_title>Identification of New Markers of Atrial Myopathy in Patients With Embolic Stroke of Undetermined Source (ESUS) From MRI 4D Data</brief_title>
  <acronym>IRM 4D-AVC</acronym>
  <official_title>Identification of New Markers of Atrial Myopathy in Patients With Embolic Stroke of Undetermined Source (ESUS) From MRI 4D Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial myopathy is considered to be the underlying cause of a large proportion of embolic&#xD;
      strokes of undetermined source. However, the definition of this atrial condition is not well&#xD;
      delineated while its identification could lead to prescription on anticoagulation in order to&#xD;
      avoid stroke recurences. This study aims to identify new markers of atrial myopathy and&#xD;
      choosed a multi parametric approach with electrical, echographical, biological and 4D flow&#xD;
      CMR derived markers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">July 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean flow velocities in the left atrium</measure>
    <time_frame>One Day</time_frame>
    <description>Velocity magnitude (cm/s) for all atrial voxels and all cardiac frames will be plotted in a histogram and normalized by the total number of voxels to allow comparisons between subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal flow velocities in the left atrium</measure>
    <time_frame>One Day</time_frame>
    <description>Velocity magnitude (cm/s) for all atrial voxels and all cardiac frames will be plotted in a histogram and normalized by the total number of voxels to allow comparisons between subjects. Local peak velocity will be obtained by averaging 5 percent of all maximum values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrium stasis</measure>
    <time_frame>One Day</time_frame>
    <description>Velocity magnitude (cm/s) for all atrial voxels and all cardiac frames will be plotted in a histogram and normalized by the total number of voxels to allow comparisons between subjects. Local peak velocity will be obtained by averaging 5 percent of all maximum values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vortex size</measure>
    <time_frame>One Day</time_frame>
    <description>Vortices in the isolated LA chamber were detectedusing the Lambda2 (λ2) method, which is an objective and widelyaccepted method to identify 3D vortice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrium volume</measure>
    <time_frame>One Day</time_frame>
    <description>Extracted from 3D MR reconstruction, expressed in mL/m2 of body surface area.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Embolic Stroke of Undetermined Source</condition>
  <arm_group>
    <arm_group_label>Patients with embolic strokes of undetermined source.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients over 18 years old, with embolic strokes of undetermined source, fulfilling the TOAST criteria. The intervention consists of a 4D Flow MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with non-paroxysmal AF.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients over 18 years old, with non-paroxysmal AF. The intervention consists of a 4D Flow MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heathy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will include volunteers over 45 years old with no history of cardio-vascular or neuro-vascular disease. The last will be certified by a pre inclusion protocol containing a medical consultation, a Holter ECG and a trans-thoracic echocardiography. The age of 45 was chosen to get comparable age group and set the analyses free of the age-related effect on the cardiac hemodynamic. The intervention consists of an ECG, holter ECG, Trans thoracic echocardiography ETT, Blood sample and 4D Flow MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESUS and non-paroxysmal AF patients with cardiac MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESUS and non-paroxysmal AF patients (fulfilling the group 1 et 2 criteria) and who had had cardiac MRI, in a retrospective way. It corresponds to retrospective inclusion of patients which had MRI in the year before the beginning of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>4D Flow MRI</intervention_name>
    <description>Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.</description>
    <arm_group_label>Heathy volunteers</arm_group_label>
    <arm_group_label>Patients with embolic strokes of undetermined source.</arm_group_label>
    <arm_group_label>Patients with non-paroxysmal AF.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical consultation with 12 leads ECG</intervention_name>
    <description>Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.</description>
    <arm_group_label>Heathy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Holter ECG</intervention_name>
    <description>48 hours ECG recording</description>
    <arm_group_label>Heathy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Trans thoracic echocardiography</intervention_name>
    <description>Trans thoracic echocardiography with standard measures performes in the core lab.</description>
    <arm_group_label>Heathy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.</description>
    <arm_group_label>Heathy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard MRI</intervention_name>
    <description>Acquisitions of MR imagining</description>
    <arm_group_label>ESUS and non-paroxysmal AF patients with cardiac MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Groupe1:Ischemic embolic stroke of undetermined source (ESUS) according to TOAST criteria&#xD;
        (N =10)&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Non-gap ischemic stroke diagnosed on MRI or CT scan of the brain (gap stroke defined&#xD;
             as a cerebral infarction ≤ 1.5 cm / ≤2.0 cm on diffusion sequences).&#xD;
&#xD;
          -  No major cardio-embolic source (episode of atrial fibrillation or flutter &gt; 6min,&#xD;
             intracardiac thrombus, LVEF &lt;30 percent recent myocardial infarction (&lt;4 weeks),&#xD;
             mitral stenosis, valvular vegetation or infectious endocarditis).&#xD;
&#xD;
          -  Absence of atherosclerosis causing stenosis ≥ 50 percent of the lumen of the intra or&#xD;
             extra cranial arteries that vascularise the infarcted cerebral area.&#xD;
&#xD;
          -  No other specific cause identified (arteritis, arterial dissection,&#xD;
             migraine/vaso-spasm, toxic cause).&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
          -  Patient who signed the consent&#xD;
&#xD;
        Group 2: Non-paroxysmal AF (N=10)&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Subject with documented non-paroxysmal AF&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
          -  Patient who signed the consent&#xD;
&#xD;
        Group 3: Healthy volunteers (N=10)&#xD;
&#xD;
        Pre-inclusion criteria :&#xD;
&#xD;
          -  Age ≥ 45 years old&#xD;
&#xD;
          -  Patient with no documented cardiac or neuro-vascular history&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
          -  Patient who signed the consent&#xD;
&#xD;
          -  Registration on the VRB file (Volontaires Recherches Biomédicales,&#xD;
             https://vrb.sante.gouv.fr) or response to the published announcement&#xD;
&#xD;
        Criteria for inclusion :&#xD;
&#xD;
          -  ECG in sinus rhythm&#xD;
&#xD;
          -  Holter ECG: no AF&#xD;
&#xD;
          -  Normal Trans thoracic echocardiography&#xD;
&#xD;
          -  Patient with no neuro-vascular history&#xD;
&#xD;
        Group 4: Stroke-ESUS or non-paroxysmal AF with cardiac MRI (N=10)&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Subject with a documented stroke-ESUS or documented non-paroxysmal FA&#xD;
&#xD;
          -  Subject with cardiac MRI&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
          -  Subject having given its non-opposition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Groupe1: Ischemic embolic stroke of undetermined source (ESUS) according to TOAST criteria&#xD;
        (N =10)&#xD;
&#xD;
          -  Risk of pregnancy or pregnancy (proven on interrogation data or pregnancy test).&#xD;
&#xD;
          -  Contraindication to MRI ferromagnetic material (in particular pacemaker, implantable&#xD;
             defibrillator, cardiac valve prosthesis, cochlear implant, neuro-stimulator, implanted&#xD;
             automated injection material, intraocular metallic foreign body, neurosurgical and&#xD;
             vascular clips, claustrophobia)&#xD;
&#xD;
          -  Less than 8 weeks after implantation of a stent&#xD;
&#xD;
          -  Subject participating in another intervention research including a period of exclusion&#xD;
             still in progress at the pre-inclusion stage.&#xD;
&#xD;
        Group 2: Non-paroxysmal AF (N=10)&#xD;
&#xD;
          -  Risk of pregnancy or pregnancy (proven on interview data or pregnancy test).&#xD;
&#xD;
          -  Contraindication to MRI ferromagnetic material (in particular pacemaker, implantable&#xD;
             defibrillators, cardiac valve prosthesis, cochlear implant, neurostimulators,&#xD;
             implanted automated injection equipment, intraocular metallic foreign body,&#xD;
             neurosurgical and vascular clips, claustrophobia).&#xD;
&#xD;
          -  Less than 8 weeks after implantation of a stent&#xD;
&#xD;
          -  Subject participating in another intervention research including a period of exclusion&#xD;
             still in progress at the pre-inclusion stage.&#xD;
&#xD;
        Group 4: Stroke-ESUS or non paroxysmal AF with cardiac MRI (N=10)&#xD;
&#xD;
          -  History of neuro-vascular or cardiac pathology&#xD;
&#xD;
          -  Risk of pregnancy or pregnancy (proven on interrogation data or pregnancy test).&#xD;
&#xD;
          -  Contraindication to MRI (ferromagnetic material (in particular pacemaker, implantable&#xD;
             defibrillator, cardiac valve prosthesis, cochlear implant, neuro-stimulator, implanted&#xD;
             automated injection material, intraocular metallic foreign body, neurosurgical and&#xD;
             vascular clips, claustrophobia)&#xD;
&#xD;
          -  Subject participating in another intervention research including a period of exclusion&#xD;
             still in progress at the pre-inclusion stage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe CHEVALIER, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief of the Arrhythmia Unit at the Academic Hospital of Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe CHEVALIER, Pr</last_name>
    <phone>4.72.35.70.27</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.chevalier@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sihem BEN AOUICHA, PhD</last_name>
    <phone>4 72 35 69 42</phone>
    <phone_ext>+33</phone_ext>
    <email>Sihem.ben-aouicha@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'urgences neuro-vasculaires, service de neurologie vasculaire Hôpital neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura MECHTOUFF, MD</last_name>
      <phone>4.72.35.67.47</phone>
      <phone_ext>+33</phone_ext>
      <email>laura.mechtouff@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Imagerie médicale Hôpital neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe DOUEK, Pr</last_name>
      <phone>4.72.35.72.33</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.douek@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service rythmologie, Hôpital cardiologique Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CHEVALIER, Pr</last_name>
      <phone>4.72.35.70.17</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.chevalier@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sihem BEN AOUICHA, PhD</last_name>
      <phone>4.72.35.76.77</phone>
      <phone_ext>+33</phone_ext>
      <email>sihem.ben-aouicha@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Myopathy</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>ESUS</keyword>
  <keyword>MRI</keyword>
  <keyword>blood velocity</keyword>
  <keyword>left atrium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Embolic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

